PENTAPHARM

Der Packungsbeileger dient nur als erste Information. Der relevante Packungsbeileger liegt der Ware bei. The datasheet is for information purposes only. The current datasheet will be enclosed with product shipment.

Pefabloc® FG

Description: Pefabloc® FG binds with a high affinity to fibrinogen, inhibits fibrin polymerization, modifies the

mechanical properties of fibrin clots and can dissociate non-stabilized fibrin gels.

Application: Pefabloc® FG is added to fibrinogen containing reaction mixtures to inhibit disturbing fibrin-related

turbidity, gel formation and fibrin deposition in diagnostic and preparative procedures (e. g. measurement of thrombin generation in plasma). Pefabloc® FG is also used to inhibit fibrin formation during purification and processing of clotting factors and other plasma proteins.

Recommended Pefabloc® FG concentrations:

Application:	Concentration
Gelation prevention:	
des-AB-fibrin	0.5-2.3 mM
des-A-fibrin	2.3 mM
human plasma, HC-II test	0.5 mg/ml
bov. fibrinogen 0.2% / thrombin 0.5 U/ml	1.5 mg/ml
Clot liquefaction:	
des-AB-fibrin	15.0 mM
des-A-fibrin	1.0 mM

Formula: H-Gly-Pro-Arg-Pro-OH-AcOH

MW: 485.5

Solubility: readily soluble in water

Storage: May be used by the expiry date given on the label when stored unopened, protected from

moisture, in the dark, 2 - 8°C. Avoid contamination of the reagents by micro-organisms.

Shipment of product does not require cooling during the time of transportation.

References: Furlan M, Rupp C, Beck E A, Svendsen L.

Effect of calcium and synthetic peptides on fibrin polymerization.

Thromb Haemost 1982; 47: 118-21.

Prasa D, Svendsen L, Stürzebecher J.

The ability of thrombin inhibitors to reduce the thrombin activity generated in plasma on extrinsic

and intrinsic Activation.

Thromb Haemost 1997; 77: 498-503.

Package size: Bulk [g] Code: 099-01

FOR RESEARCH USE ONLY. NOT FOR HUMAN USE OR DRUG USE.

www.loxo.de - info@loxo.de